Evidence map›Paper›PMID 38359001›Full record

ArticlePloS one2024

Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.

Isabella Zuppo Laper, Cecilia Camacho-Hubner, Rafaela Vansan Ferreira, Claudenice Leite Bertoli de Souza, Marcus Vinicius Simões, Fabio Fernandes, Edileide de Barros Correia, Ariane de Jesus Lopes de Abreu, Guilherme Silva Julian

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Isabella Zuppo LaperIQVIA Brazil, São Paulo, São Paulo, Brazil.ORCID 0000-0003-0473-264X
Cecilia Camacho-HubnerPfizer Global, New York City, New York, United States of America.
Rafaela Vansan FerreiraIQVIA Brazil, São Paulo, São Paulo, Brazil.ORCID 0000-0001-6662-5992
Claudenice Leite Bertoli de SouzaPfizer Brazil, São Paulo, São Paulo, Brazil.
Marcus Vinicius SimõesMedical School of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Fabio FernandesHeart Institute, University of São Paulo, São Paulo, Brazil.
Edileide de Barros CorreiaInstituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
Ariane de Jesus Lopes de AbreuIQVIA Brazil, São Paulo, São Paulo, Brazil.ORCID 0000-0002-5599-0991
Guilherme Silva JulianPfizer Brazil, São Paulo, São Paulo, Brazil.ORCID 0000-0002-3487-2240
Universidade de São Paulo · BRInstituto Dante Pazzanese de Cardiologia · BRPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo identify and describe the profile of potential transthyretin cardiac amyloidosis (ATTR-CM) cases in the Brazilian public health system (SUS), using a predictive machine learning (ML) model.

methodsThis was a retrospective descriptive database study that aimed to estimate the frequency of potential ATTR-CM cases in the Brazilian public health system using a supervised ML model, from January 2015 to December 2021. To build the model, a list of ICD-10 codes and procedures potentially related with ATTR-CM was created based on literature review and validated by experts.

resultsFrom 2015 to 2021, the ML model classified 262 hereditary ATTR-CM (hATTR-CM) and 1,581 wild-type ATTR-CM (wtATTR-CM) potential cases. Overall, the median age of hATTR-CM and wtATTR-CM patients was 66.8 and 59.9 years, respectively. The ICD-10 codes most presented as hATTR-CM and wtATTR-CM were related to heart failure and arrythmias. Regarding the therapeutic itinerary, 13% and 5% of hATTR-CM and wtATTR-CM received treatment with tafamidis meglumine, respectively, while 0% and 29% of hATTR-CM and wtATTR-CM were referred to heart transplant.

conclusionOur findings may be useful to support the development of health guidelines and policies to improve diagnosis, treatment, and to cover unmet medical needs of patients with ATTR-CM in Brazil.

Indexed as

Amyloid Neuropathies, FamilialAmyloidosisCardiomyopathiesBrazilHumansMachine LearningPrealbuminPublic HealthRetrospective StudiesPrealbumin

Identifiers

PMID38359001
PMCPMC10868784
OpenAlexW4391839383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.